



RECEIVED

JUL 19 2002

TECH CENTER 1600/2900

VPI/00-117

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : J.-D. Carrier & G. Benchley
Application No.: 09/877,832 Confirmation No.: 9982
Filed : June 7, 2001
For : CASPASE INHIBITORS AND USES THEREOF
Group Art Unit : 1624
Examiner : V. Balasubramanian

Cambridge, Massachusetts
July 15, 2002

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their attorney, make of record the documents listed below (copies enclosed herewith). A completed Form PTO-1449 listing all of the documents is enclosed herewith in duplicate.


Foreign Patent Applications

<u>Applicant</u>	<u>Publication No.</u>	<u>Publication Date</u>
Sanofi Winthrop, Inc.	WO 95/33751	December 14, 1995
Vertex Pharmaceuticals Incorporated	WO 95/35308	December 28, 1995
Idun Pharmaceuticals, Incorporated	WO 98/11109	March 19, 1998

These documents were cited in an International Search Report (copy enclosed) in this application's counterpart PCT application (PCT/US01/18243).

Applicants request that these documents: (1) be fully considered by the Examiner during examination of this application, and (2) be printed on any patent that may issue from this application. Applicants also request that a copy of the enclosed Form PTO-1449 duly initialed by the Examiner be forwarded to the undersigned with the next communication.

Respectfully submitted,



Lisa A. Dixon (Reg. No. 40,995)
Attorney for Applicants

VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Tel.: (617)444-6396



Rev. 04/01

RECEIVED
JUL 19 2002
TECH CENTER 1600/2900

Docket No. VPI/00-117

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : J.-D. Carrier & G. Benchley
Application No.: 09/877,832 Confirmation No.: 9982
Filed : June 7, 2001
For : CASPASE INHIBITORS AND USES THEREOF
Group Art Unit : 1624
Examiner : V. Balasubramanian

Cambridge, Massachusetts
July 15, 2002

Hon. Commissioner
for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT


Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted more than three months from the application filing date but before the mailing date of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97, this submission requires no fee.

The Director is hereby authorized to charge to Deposit Account No. 50-0725 payment of any fees required in connection with the accompanying Information Disclosure


Statement. A duplicate copy of this letter is transmitted
herewith.

Respectfully submitted,



Lisa A. Dixon (Reg. No. 40,995)
Attorney for Applicants

VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Tel.: (617) 444-6396



Certificate Of Mailing Under 37 C.F.R. § 1.10

Express Mailing No. EV 019 224 570 US

Date of Deposit: July 16, 2002



I hereby certify that the following documents:

1. a Transmittal Letter for IDS (in duplicate);
2. an Information Disclosure Statement Under 37 C.F.R. §§1.56 and 1.97 (in duplicate);
3. Foreign Patent Applications;
4. PTO-1449 Form (with a copy of cited referenced 1-3); and
5. this return postcard receipt.

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Honorable Commissioner for Patents, Washington D.C. 20231

Karen DiRocco

(type or printed name of person mailing document(s))

Karen DiRocco

(signature of person mailing document(s))

RECEIVED
JUL 19 2002
TECH CENTER 1600/2900